SCHEMBL3036134

SCHEMBL3036134

CCC(CC)(N(c1ccc2c(C(=O)N3CCCC3)nn(C)c2c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1)P(=O)(O)O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
DRD2 P14416 2/20 0.35
HTR2A P28223 2/20 0.35
GAA P10253 3/20 0.33
POLB P06746 3/20 0.33
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32
RECQL P46063 1/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
RBP4 P02753 1/20 0.31
TSHR P16473 1/20 0.31
HPGD P15428 1/20 0.31
HSD11B1 P28845 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3036210 0.85 USP2 (0.42) GAAPOLBSMN1; SMN2RXFP1
SCHEMBL3033765 0.83 GRM4 (0.39) GRM4MEN1KMT2ADRD2HTR2A
SCHEMBL3036131 0.80 GRM4 (0.37) GRM4MEN1KMT2ADRD2HTR2A
SCHEMBL2844977 0.80 GRM4 (0.40) GRM4MEN1KMT2ADRD2HTR2A
SCHEMBL11948457 0.77 GRM4 (0.37) GRM4MEN1KMT2ADRD2HTR2A
SCHEMBL3068176 0.73 HPGD (0.40) GAAPOLBSMN1; SMN2TSHRHPGD
SCHEMBL2841138 0.72 GRM4 (0.49) GRM4MEN1KMT2AGAAPOLB
SCHEMBL2098568 0.70 ATM (0.32)
SCHEMBL3033620 0.70 HCRTR2 (0.38) TNKSTNKS2HPGDHSD11B1
SCHEMBL3028843 0.70 PRKACA (0.34) GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211923-B2 Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-03 US disclosed
US-20100210595-A1 SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210595-A1 SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS G6PC1, PYGL, PPP1CA GRM4 1798/4885MEN1 4101/4885KMT2A 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.